ClinicalTrials.gg
RecruitingNCT06587854PROFILE-AHFUpdated Sep 10, 2025

a PRagmatic Observational Study of Congestion proFILes in patiEnts With Acute Heart Failure

An observational study in Acute Heart Failure, sponsored by University Medical Center Groningen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by University Medical Center Groningen · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
270
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Heart Failure by University Medical Center Groningen — 8 open to participants now, 9 under way, 1 of them phase 3. Heart Failure · University Medical Center Groningen.

Planned enrollment
3rd of 10
270 · median 114
Started
2025
the only one that year
Observational
10 of 28
3 open now
Registered
23rd of 28
by date

Among the 28 studies in Heart Failure by University Medical Center Groningen, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2025, is one of 10 observational ones, and was the 23rd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

8 of the 28 studies in Heart Failure by University Medical Center Groningen are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Heart Failure by University Medical Center Groningen, or all of them as a file.
02

Study summary

The goal of this observational is to study the prevalence of distinct congestion phenotypes and study their association with response to therapy and outcomes in acute heart failure patients. The main question[s] it aims to answer [is/are]:

  • Primary objective: to study the prevalence of distinct congestion phenotypes
  • Other objectives (including):

    • Response to therapy as assessed by

      • Natriuresis after 24 hours
      • Rehospitalization and/or deats after 6 months
    • Length of hospital stay
    • Congestion at discharge
    • Changes in filling pressures over time
    • Relationship between liver stiffness, as assessed with Fibroscan and congestion
    • Substudy: glycosaminoglycan netword and endothial glycocalyx

Participants will undergo several extra study related measurements:

  • Assessment of filling pressures with ultrasound
  • Ultrasound investigation of the lungs and kidneys
  • Fibroscan of the liver
  • Sidestream darkfield imaging sublingual
  • As part of substudy GLYCO-AHF: skin biopsy to determine glycocalyx, as well as salt and water content.
  • As part of substudy PREACH-AHF: the effects of peripheral venous congestion and endothelial dysfunction on a large screen of plasma proteins
Read the detailed description

Objective: to study the prevalence of distinct congestion phenotypes and investigate their association with response to therapy and outcomes in acute heart failure patients.

Study design: Observational, prospective study

Study population: 270 patients admitted with the primary diagnosis of acute heart failure requiring intravenous loop diuretics.

Main study parameters/endpoints:

To identify distinct congestion phenotypes and study their association with response to therapy and outcomes

Secondary outcomes: total natriuresis after 24 hours, and first occurrence of all-cause mortality or heart failure rehospitalisation at 6 months Exploratory outcomes include: length of hospital stay, congestion at discharge and changes in filling pressures over time. Furthermore, as part of the GLYCO-AHF substudy: the expression of glycosaminoglycans and, as part of the PREACH-AHF substudy: the effects of peripheral venous congestion and endothelial dysfunction on a large screen of plasma proteins.

03

Conditions studied

  • Acute Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients admitted to the hospital with a primary diagnosis of acute heart failure

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to give written
  • Age ≥ 18 years
  • Male or female
  • Primary diagnosis of acute heart failure at presentation, with signs and symptoms of tissue decongestion. Diagnosis is based on the criteria in the ESC HF guidelines (1)
  • Requirement of intravenous loop diuretics

Exclusion criteria

Exclusion Criteria:

  • Patients with severe kidney dysfunction (in need for ultrafiltration or dialysis)
  • Previous participation in this study
  • Inability to follow instructions
  • Dyspnoea or oedema primarily due to non-cardiac causes
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
270 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. To study the prevalence of distinct congestion phenotypes

    Based on the degree of congestion and edema in combination with intravascular pressures, patients will be classified into different phenotypes (high/low intravascular pressures and extensive/minimal edema.

    Time frame: From date of hospital admission untill the date of discharge (from this admission), with an expected discharge after 5 to 10 days after admission.

Secondary outcomes

  1. Total natriuresis after 24 hours

    To assess this, urine is collected for 24 hours after the first administration of diuretics according to the hospital protocol and natriuresis is calculated as the total amount of diuresis (L) multiplied by the urinary sodium concentration (mmol/L).with natriuresis as the primary outcome measure.

    Time frame: 24 hours

  2. Rehospitalization and/or death after 6 months

    Time frame: 180 days

Other outcomes

  1. Congestion at discharge

    Congestion at discharge will be assessed by several measures; clinical symptoms (e.g. orthopnoea, dyspnoea), physical examination (e.g. oedema, rales, jugular venous pressure), ultrasound examination (lungs, heart, inferior vena cava,.

    Time frame: Date of discharge, or maximum two days before. Expected to be between 5-10 days after admission.

  2. Changes in filling pressures over time

    Using either a Swan Ganz catheter (if present as part of standard of care) or echocardiography, intravasculair filling pressures will be measured daily.

    Time frame: From date of hospital admission untill the date of discharge, or maximum two days before. Expected to be between 5-10 days after admission.

  3. Length of stay

    Number of days of the index hospitalization

    Time frame: Variable, from date of admission untill date of discharge. Expected to be between 5-10 days after admission.

  4. Liver stiffness, as assessed with Fibroscan

    Congestion of the liver reflected by liver stifness will be determined after admission and at discharge (with maximum two days before).

    Time frame: From date of hospital admission untill the date of discharge, or maximum two days before. Expected to be between 5-10 days after admission.

  5. Differences in microvasculature

    Subligual sidestream darkfield imaging will be performed at day 1 or 2 and will be repeated at discharge (or maximum two days before). This technique allows for a detailed observation of capillary blood flow, capillary density and glycocalyx integrity. Comparing the microvasculature between the different congestion phenotype groups, as well as studying changes in the microvasculature from admission to discharge will provide novel information with regards to the microvasculature in AHF patients.

    Time frame: From date of hospital admission untill the date of discharge, or maximum two days before. Expected to be between 5-10 days after admission.

  6. (Substudy GLYCO-AHF): Differences in glycosaminoglycan network

    A skin biopsy will be performed at day 1 or 2. At discharge, or maximum two days before, patients will receive a second skin biopsy. With the biopsy the glycosaminoglycan network and glygocalyx can be determined. Cryosections will be stained using available antibodies for glycosaminoclycans, whereafter their immunochemical expression will be quantified. The expression will be compared between both the different patient groups (based on phenotype) as well as between the two biopsies (at admission and at discharge).

    Time frame: From date of hospital admission untill the date of discharge, or maximum two days before. Expected to be between 5-10 days after admission.

  7. (Substudy PREACH-AHF): Effects of peripheral venous congestion on plasma proteins

    To study the effect of peripheral venous congestion and endothelial dysfunction on plasma proteins, blood samples will be taken via an intravenous line before and after inflating a pressure cuff, while a pressure transducer measures the peripheral venous pressure. Patients will also undergo a reactive hyperaemia index measurement to investigate the link between plasma proteins and endothelial dysfunction. These measurements will be performed at discharge or a maximum of 2 days before.

    Time frame: Date of discharge, or maximum two days before.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jun 2028, 37 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 37 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2024
First posted
Sep 19, 2024
StartActual
May 1, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 31, 2029
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06587854
Responsible party
Jozine ter Maaten (Principal Investigator, University Medical Center Groningen) — Principal investigator
First posted
Sep 19, 2024
Start date
May 1, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 10, 2025

Study contacts

Jozine M. ter Maaten, MD, PhD
Contact
j.m.ter.maaten@umcg.nl
+31503616161
Lara E.E.C. Zonneveld, MD
Contact
+31503616161

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion